Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10746393 | Parkinsonism & Related Disorders | 2005 | 4 Pages |
Abstract
We investigated the clinical efficacy and tolerability of 45Â mg/day mosapride, a selective 5-hydroxytryptamine type 4 (5-HT4) agonist, in an open-label study involving five patients with Parkinson's disease (PD) who had response fluctuations (RFs). 'On' time and motor function scores were determined, and gastric motility was measured by a radionuclide gastric emptying (GE) test, the most reliable quantitative method available. We found that mosapride therapy significantly shortened GE half-time, reduced RFs, and improved motor functions in all patients. There were no adverse reactions. We conclude that selective 5-HT4 agonist therapy is beneficial for patients with PD who have RFs.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Hirohide Asai, Fukashi Udaka, Makito Hirano, Takeshi Minami, Masaya Oda, Tamotsu Kubori, Kazuto Nishinaka, Masakuni Kameyama, Satoshi Ueno,